

Announcement no. 30/2008

To OMX The Nordic Exchange Copenhagen and the press

Vedbaek, June 27, 2008

**Major shareholder announcement**

Exiqon A/S today received information from Danske Bank, that the Danske Bank Group – including Danica Pension Livsforsikring and Danske Fund FCP – through acquisition today of 502,300 shares now owns 1,804,514 shares of a nominal value of each DKK 1 corresponding to 5,99% of the share capital and 5,99% of the voting rights in Exiqon A/S.

**For more information, please contact:**

**Exiqon A/S**

Lars Kongsbak, President and CEO, tel. + 45 40 90 21 01  
Hans Henrik Chrois Christensen, CFO, tel. +45 40 90 2131

**About Exiqon**

Exiqon's corporate mission is to combine leading-edge scientific expertise in gene expression with our proprietary LNA™ technology. Exiqon's products, services and scientific staff enable life science researchers to make groundbreaking discoveries. Moreover, Exiqon is addressing the unmet need for a new approach to the diagnosis of cancer. Exiqon's products are based on patented technology (LNA™ or Locked Nucleic Acids) that facilitates very precise and sensitive analysis of nucleic acids. Exiqon aims to expand the existing product offering for research use as well as to develop new proprietary molecular diagnostic products. Exiqon, through a number of recent initiatives, has positioned itself as a significant player in applying miRNA as the key biomarker in cancer diagnostics. Exiqon has facilities in Denmark, Boston (MA) and Tustin (CA).

-oo0oo-